Metraipolis › archive › dc_fb32323975a8

Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome — Europe PMC PMID:42647509

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42647509
DOI
10.1371/journal.pone.0349155
License (as archived)
solo-consultazione
Archived
2026-10-08T01:47:14.411Z
SHA-256 of the archived text
330d7109a60f0315469c3d4ca1508252ffa24b5b43ebe561f9e66ea240d2ca2f
Stable URL of this page
https://metraipolis.com/documento/dc_fb32323975a8

How to cite

Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome — Europe PMC PMID:42647509 — Europe PMC (en), https://europepmc.org/article/MED/42647509 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fb32323975a8 (Metraipolis archive dc_fb32323975a8, sha256 330d7109a60f0315469c3d4ca1508252ffa24b5b43ebe561f9e66ea240d2ca2f)
BibTeX
@misc{dcfb32323975a8,
  title = {Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome — Europe PMC PMID:42647509},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42647509},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fb32323975a8; sha256 330d7109a60f0315469c3d4ca1508252ffa24b5b43ebe561f9e66ea240d2ca2f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42647509. Agents can read the archived copy with the MCP tool read_document.